• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is CONMED (CNMD) A Bargain As Earnings And 2026 Guidance Reset Expectations?

    Simply Wall St·10/31/2026 05:38:39
    語音播報

    CONMED (CNMD) just posted its third quarter update, reporting sales of US$335.56 million and net income of US$19.8 million, along with slightly narrowed full year net sales guidance for 2026.

    CONMED’s latest earnings and slightly tighter 2026 sales guidance landed against a choppy trading backdrop. The share price fell 10.1% over the past week and 3.1% on the day, while the year-to-date share price return of 9.3% contrasts with a flat 1-year total shareholder return and much weaker 3 and 5 year total shareholder returns, suggesting recent momentum is fragile and investor views on longer term risk and reward remain cautious.

    Spot similar setups to CONMED’s recent earnings reset by scanning curated 18 high quality undiscovered gems with strong fundamentals that the wider market may still be ignoring.

    CONMED now trades at a steep implied discount to some fair value estimates despite only a modest gap to analyst targets after this pullback. Is the market correctly pricing in long term execution risk, or is it overdoing the caution?

    Most Popular Narrative: 2.7% Undervalued

    Against CONMED’s last close at $44.29, the most followed narrative pegs fair value at $45.50 using an 8.6% discount rate. This suggests a small valuation gap rather than a deep mispricing.

    CONMED’s decision to exit lower growth gastroenterology lines and concentrate capital and commercial resources on high growth, high margin platforms such as AirSeal, Buffalo Filter and BioBrace sharpens the product mix. This can support organic revenue growth and improve consolidated gross margin and earnings.

    See why 3 investors see CONMED as 3% undervalued.

    Result: Fair Value of $45.50 (UNDERVALUED)

    Still, if organic growth stays under pressure and higher interest costs bite into CONMED’s financial flexibility, the fair value story could quickly feel more demanding.

    Find out about the key risks to this CONMED narrative.

    Next Steps

    Sentiment around CONMED is clearly split. Consider moving quickly, reviewing the underlying data, and weighing both sides of the story for yourself with 4 key rewards and 1 important warning sign

    Looking for more investment ideas beyond CONMED?

    If CONMED has you thinking harder about risk, reward, and timing, broaden your watchlist now with fresh ideas before the next move leaves you playing catch-up.